Guardian Partners Inc. purchased a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) during the third quarter, HoldingsChannel reports. The institutional investor purchased 2,000 shares of the medical research company’s stock, valued at approximately $827,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Natera during the second quarter worth about $2,962,770,000. Arrowstreet Capital Limited Partnership raised its position in Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after buying an additional 11,793 shares during the last quarter. Maverick Capital Ltd. raised its position in Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after buying an additional 227,605 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after acquiring an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in Natera in the 2nd quarter valued at approximately $199,960,000. 99.90% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $414.22, for a total value of $1,242,660.00. Following the completion of the transaction, the insider directly owned 106,914 shares of the company’s stock, valued at approximately $44,285,917.08. This trade represents a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brophy sold 478 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16. Following the transaction, the chief financial officer owned 51,637 shares in the company, valued at approximately $14,159,898.14. The trade was a 0.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 52,985 shares of company stock worth $16,119,137. 5.05% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
A number of equities analysts have weighed in on NTRA shares. Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Royal Bank Of Canada lifted their price objective on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a report on Friday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Thursday, October 15th. Guggenheim boosted their price objective on shares of Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Sanford C. Bernstein assumed coverage on shares of Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $374.64.
Read Our Latest Report on Natera
Natera Trading Up 1.8%
NTRA opened at $413.38 on Thursday. The business’s 50-day simple moving average is $363.64 and its 200 day simple moving average is $280.16. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41.
Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business’s revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company earned ($0.74) earnings per share. As a group, research analysts predict that Natera, Inc. will post -1.05 earnings per share for the current year.
Natera Company Profile
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.
In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.
Featured Stories
- Five stocks we like better than Natera
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
